• eikon
• 13 Ottobre 2022
• NEWS
• 0 Comments

We invite you to join us in our meeting room at the Intercontinental Suite #510/511 and learn more about our capabilities: In order to schedule a meeting please contact luca.covello@polycrystalline.it.

• eikon
• 8 Ottobre 2022
• NEWS
• 0 Comments

New Crystalline Forms of Dex-Lansoprazole Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Kapidex (dexlansoprazole). This DEP002 product contains a new and stable crystal of dexlansoprazole which circumvents Takeda’s intellectual property. Kapidex is a proton pump inhibitor that obtained FDA approval in 2009 by Takeda Pharmaceuticals for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease …

• eikon
• 4 Ottobre 2022
• NEWS
• 0 Comments

PolyCrystalLine discovered a novel crystalline form of Minodronic Acid and filed a patent application. For additional information contact info@polycrystalline.it